{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:11:53Z","timestamp":1789413113472,"version":"build-2803163510"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04070-1","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T01:01:42Z","timestamp":1728954102000},"page":"907-919","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effect of antidiabetic drugs on bone metabolism: a concise review"],"prefix":"10.1007","volume":"87","author":[{"given":"Stavroula","family":"Psachna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eleni","family":"Chondrogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Polymeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Chatzigeorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Chronopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symeon","family":"Tournis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"4070_CR1","first-page":"1","volume":"843","author":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","year":"1994","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, Report of a WHO Study Group. World Health Organ Tech. Rep. Ser. 843, 1\u2013129 (1994)","journal-title":"World Health Organ Tech. Rep. Ser."},{"key":"4070_CR2","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"H. Sun, P. Saeedi, S. Karuranga, M. Pinkepank, K. Ogurtsova, B.B. Duncan et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diab. Res Clin. Pr. 183, 109119 (2022)","journal-title":"Diab. Res Clin. Pr."},{"issue":"9","key":"4070_CR3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2337\/dc07-2426","volume":"31","author":"LD Mastrandrea","year":"2008","unstructured":"L.D. Mastrandrea, J. Wactawski-Wende, R.P. Donahue, K.M. Hovey, A. Clark, T. Quattrin, Young women with type 1 diabetes have lower bone mineral density that persists over time. Diab. Care 31(9), 1729\u20131735 (2008)","journal-title":"Diab. Care"},{"issue":"10","key":"4070_CR4","first-page":"1085","volume":"10","author":"B Lecka-Czernik","year":"2009","unstructured":"B. Lecka-Czernik, Bone as a target of type 2 diabetes treatment. Curr. Opin. Investig. Drugs 10(10), 1085\u20131090 (2009)","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"3","key":"4070_CR5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2213-8587(21)00347-8","volume":"10","author":"LC Hofbauer","year":"2022","unstructured":"L.C. Hofbauer, B. Busse, R. Eastell, S. Ferrari, M. Frost, R. M\u00fcller et al. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diab. Endocrinol. 10(3), 207\u2013220 (2022)","journal-title":"Lancet Diab. Endocrinol."},{"issue":"5","key":"4070_CR6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.tem.2022.02.006","volume":"33","author":"A Sheu","year":"2022","unstructured":"A. Sheu, J.R. Greenfield, C.P. White, J.R. Center, Assessment and treatment of osteoporosis and fractures in type 2 diabetes. Trends Endocrinol. Metab. 33(5), 333\u2013344 (2022)","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"4070_CR7","doi-asserted-by":"crossref","first-page":"e024067","DOI":"10.1136\/bmjopen-2018-024067","volume":"9","author":"H Wang","year":"2019","unstructured":"H. Wang, Y. Ba, Q. Xing, J.-L. Du, Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open 9(1), e024067 (2019)","journal-title":"BMJ Open"},{"issue":"3","key":"4070_CR8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00198-019-05224-y","volume":"31","author":"NH Rasmussen","year":"2020","unstructured":"N.H. Rasmussen, J. Dal, F. de Vries, J.P. van den Bergh, M.H. Jensen, P. Vestergaard, Diabetes and fractures: new evidence of atypical femoral fractures? Osteoporos. Int 31(3), 447\u2013455 (2020)","journal-title":"Osteoporos. Int"},{"issue":"4","key":"4070_CR9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2016.153","volume":"13","author":"N Napoli","year":"2017","unstructured":"N. Napoli, M. Chandran, D.D. Pierroz, B. Abrahamsen, A.V. Schwartz, S.L. Ferrari, Mechanisms of diabetes mellitus-induced bone fragility. Nat. Rev. Endocrinol. 13(4), 208\u2013219 (2017)","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"4070_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","volume":"42","author":"TE LaMoia","year":"2021","unstructured":"T.E. LaMoia, G.I. Shulman, Cellular and molecular mechanisms of metformin action. Endocr. Rev. 42(1), 77\u201396 (2021)","journal-title":"Endocr. Rev."},{"issue":"1\u20132","key":"4070_CR11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2006.02.030","volume":"536","author":"AM Cortizo","year":"2006","unstructured":"A.M. Cortizo, C. Sedlinsky, A.D. McCarthy, A. Blanco, L. Schurman, Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur. J. Pharm. 536(1\u20132), 38\u201346 (2006)","journal-title":"Eur. J. Pharm."},{"issue":"3","key":"4070_CR12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbrc.2008.08.034","volume":"375","author":"I Kanazawa","year":"2008","unstructured":"I. Kanazawa, T. Yamaguchi, S. Yano, M. Yamauchi, T. Sugimoto, Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys. Res Commun. 375(3), 414\u2013419 (2008)","journal-title":"Biochem Biophys. Res Commun."},{"issue":"06","key":"4070_CR13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-2007-992786","volume":"116","author":"L Schurman","year":"2008","unstructured":"L. Schurman, A. McCarthy, C. Sedlinsky, M. Gangoiti, V. Arnol, L. Bruzzone et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp. Clin. Endocrinol. Diab. 116(06), 333\u2013340 (2008)","journal-title":"Exp. Clin. Endocrinol. Diab."},{"issue":"6","key":"4070_CR14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11914-023-00828-0","volume":"21","author":"TJ de Vries","year":"2023","unstructured":"T.J. de Vries, A.S. Kleemann, J. Jin, T. Schoenmaker, The differential effect of metformin on osteocytes, osteoblasts, and osteoclasts. Curr. Osteoporos. Rep. 21(6), 743\u2013749 (2023)","journal-title":"Curr. Osteoporos. Rep."},{"issue":"1","key":"4070_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13287-020-1565-6","volume":"11","author":"M Khorraminejad-Shirazi","year":"2020","unstructured":"M. Khorraminejad-Shirazi, M. Sani, T. Talaei-Khozani, M. Dorvash, M. Mirzaei, M.A. Faghihi et al. AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells. Stem Cell Res. Ther. 11(1), 45 (2020)","journal-title":"Stem Cell Res. Ther."},{"issue":"4","key":"4070_CR16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cbf.3025","volume":"32","author":"JJ Patel","year":"2014","unstructured":"J.J. Patel, O.R. Butters, T.R. Arnett, PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell Biochem. Funct. 32(4), 368\u2013377 (2014)","journal-title":"Cell Biochem. Funct."},{"issue":"5","key":"4070_CR17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","volume":"31","author":"SE Kahn","year":"2008","unstructured":"S.E. Kahn, B. Zinman, J.M. Lachin, S.M. Haffner, W.H. Herman, R.R. Holman et al. Rosiglitazone-associated fractures in type 2 diabetes. Diab. Care 31(5), 845\u2013851 (2008)","journal-title":"Diab. Care"},{"issue":"7","key":"4070_CR18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","volume":"48","author":"P Vestergaard","year":"2005","unstructured":"P. Vestergaard, L. Rejnmark, L. Mosekilde, Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48(7), 1292\u20131299 (2005)","journal-title":"Diabetologia"},{"issue":"11","key":"4070_CR19","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1007\/s00125-012-2668-0","volume":"55","author":"HM Colhoun","year":"2012","unstructured":"H.M. Colhoun, S.J. Livingstone, H.C. Looker, A.D. Morris, S.H. Wild, R.S. Lindsay et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55(11), 2929\u20132937 (2012)","journal-title":"Diabetologia"},{"key":"4070_CR20","doi-asserted-by":"crossref","unstructured":"Wang Y., Yu L., Ye Z., Lin R., Sun A.R., Liu L., et al. Association of metformin use with fracture risk in type 2 diabetes: a systematic review and meta-analysis of observational studies. Front. Endocrinol. 11, 13 (2013). https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1038603\/full","DOI":"10.3389\/fendo.2022.1038603"},{"key":"4070_CR21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","volume":"77","author":"MJ Nanjan","year":"2018","unstructured":"M.J. Nanjan, M. Mohammed, B.R. Prashantha Kumar, M.J.N. Chandrasekar, Thiazolidinediones as antidiabetic agents: a critical review. Bioorg. Chem. 77, 548\u2013567 (2018)","journal-title":"Bioorg. Chem."},{"issue":"3","key":"4070_CR22","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1210\/en.2004-0735","volume":"146","author":"AA Ali","year":"2005","unstructured":"A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, R.L. Jilka, Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146(3), 1226\u20131235 (2005)","journal-title":"Endocrinology"},{"issue":"6","key":"4070_CR23","first-page":"1604","volume":"60","author":"GL Rubin","year":"2000","unstructured":"G.L. Rubin, Y. Zhao, A.M. Kalus, E.R. Simpson, Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res. 60(6), 1604\u20131608 (2000)","journal-title":"Cancer Res."},{"issue":"11","key":"4070_CR24","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1210\/jc.2005-0469","volume":"90","author":"D Seto-Young","year":"2005","unstructured":"D. Seto-Young, M. Paliou, J. Schlosser, D. Avtanski, A. Park, P. Patel et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J. Clin. Endocrinol. Metab. 90(11), 6099\u20136105 (2005)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4070_CR25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","volume":"180","author":"YK Loke","year":"2009","unstructured":"Y.K. Loke, S. Singh, C.D. Furberg, Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can. Med Assoc. J. 180(1), 32\u201339 (2009)","journal-title":"Can. Med Assoc. J."},{"key":"4070_CR26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","volume":"68","author":"Z-N Zhu","year":"2014","unstructured":"Z.-N. Zhu, Y.-F. Jiang, T. Ding, Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68, 115\u2013123 (2014)","journal-title":"Bone"},{"issue":"4","key":"4070_CR27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3803\/EnM.2021.1026","volume":"36","author":"J Ha","year":"2021","unstructured":"J. Ha, Y. Lim, M.K. Kim, H.-S. Kwon, K.-H. Song, S.H. Ko et al. Comparison of the effects of various antidiabetic medication on bone mineral density in patients with type 2 diabetes mellitus. Endocrinol. Metab. 36(4), 895\u2013903 (2021)","journal-title":"Endocrinol. Metab."},{"issue":"7","key":"4070_CR28","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.18632\/aging.204643","volume":"15","author":"C-L Yen","year":"2023","unstructured":"C.-L. Yen, C.-Y. Wu, C.-Y. Tsai, C.-C. Lee, Y.-J. Li, W.-S. Peng et al. Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study. Aging 15(7), 2721\u20132733 (2023)","journal-title":"Aging"},{"issue":"7","key":"4070_CR29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1463-1326.2012.01583.x","volume":"14","author":"SS Johnston","year":"2012","unstructured":"S.S. Johnston, C. Conner, M. Aagren, K. Ruiz, J. Bouchard, Association between hypoglycaemic events and fall\u2010related fractures in Medicare\u2010covered patients with type 2 diabetes. Diab. Obes. Metab. 14(7), 634\u2013643 (2012)","journal-title":"Diab. Obes. Metab."},{"issue":"10","key":"4070_CR30","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1210\/jc.2017-00042","volume":"102","author":"S\u0391 Paschou","year":"2017","unstructured":"S.\u0391 Paschou, A.D. Dede, P.G. Anagnostis, A. Vryonidou, D. Morganstein, D.G. Goulis, Type 2 diabetes and osteoporosis: a guide to optimal management. J. Clin. Endocrinol. Metab. 102(10), 3621\u20133634 (2017)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4070_CR31","doi-asserted-by":"crossref","first-page":"107990","DOI":"10.1016\/j.diabres.2019.107990","volume":"159","author":"Z Zhang","year":"2020","unstructured":"Z. Zhang, Y. Cao, Y. Tao, EM, J. Tang, Y. Liu et al. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: a meta\u2010analysis. Diab. Res Clin. Pr. 159, 107990 (2020)","journal-title":"Diab. Res Clin. Pr."},{"issue":"15","key":"4070_CR32","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinternmed.2009.214","volume":"169","author":"CR Dormuth","year":"2009","unstructured":"C.R. Dormuth, G. Carney, B. Carleton, K. Bassett, J.M. Wright, Thiazolidinediones and fractures in men and women. Arch. Intern. Med. 169(15), 1395 (2009)","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"4070_CR33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00774-010-0160-9","volume":"28","author":"I Kanazawa","year":"2010","unstructured":"I. Kanazawa, T. Yamaguchi, M. Yamamoto, T. Sugimoto, Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J. Bone Min. Metab. 28(5), 554\u2013560 (2010)","journal-title":"J. Bone Min. Metab."},{"key":"4070_CR34","doi-asserted-by":"crossref","unstructured":"Sohi Y.H., Golestani A., Panahi G., Tabatabaei-Malazy O., Khalagi K., Fahimfar N., et al. The association between anti-diabetic agents and osteoporosis, sarcopenia, and osteosarcopenia among Iranian older adults; Bushehr Elderly Health (BEH) program. DARU J. Pharm. Sci. (2023). https:\/\/link.springer.com\/10.1007\/s40199-023-00497-5","DOI":"10.1007\/s40199-023-00497-5"},{"issue":"2","key":"4070_CR35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2337\/dc07-1736","volume":"31","author":"M Monami","year":"2008","unstructured":"M. Monami, B. Cresci, A. Colombini, L. Pala, D. Balzi, F. Gori et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients. Diab. Care 31(2), 199\u2013203 (2008)","journal-title":"Diab. Care"},{"issue":"2","key":"4070_CR36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/22123911MTA5pMzA20","volume":"16","author":"NA Subrahmanyan","year":"2021","unstructured":"N.A. Subrahmanyan, R.M. Koshy, K. Jacob, J.M. Pappachan, efficacy and cardiovascular safety of DPP-4 inhibitors. Curr. Drug Saf. 16(2), 154\u2013164 (2021)","journal-title":"Curr. Drug Saf."},{"key":"4070_CR37","doi-asserted-by":"crossref","unstructured":"Yang Y., Zhao C., Liang J., Yu M., Qu X. Effect of dipeptidyl peptidase-4 inhibitors on bone metabolism and the possible underlying mechanisms. Front. Pharmacol. 25, 8 (2017). http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00487\/full","DOI":"10.3389\/fphar.2017.00487"},{"key":"4070_CR38","doi-asserted-by":"crossref","unstructured":"Yang Q., Fu B., Luo D., Wang H., Cao H., Chen X., et al. The multiple biological functions of dipeptidyl peptidase-4 in bone metabolism. Front. Endocrinol. 2, 13 (2022). https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.856954\/full","DOI":"10.3389\/fendo.2022.856954"},{"issue":"11","key":"4070_CR39","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","volume":"34","author":"M Monami","year":"2011","unstructured":"M. Monami, I. Dicembrini, A. Antenore, E. Mannucci, Dipeptidyl peptidase-4 inhibitors and bone fractures. Diab. Care 34(11), 2474\u20132476 (2011)","journal-title":"Diab. Care"},{"issue":"2","key":"4070_CR40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1753-0407.2011.00168.x","volume":"4","author":"MC Bunck","year":"2012","unstructured":"M.C. Bunck, M. Poelma, E.M. Eekhoff, A. Schweizer, R.J. Heine, G. Nijpels et al. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well\u2010controlled type 2 diabetes patients*. J. Diab. 4(2), 181\u2013185 (2012)","journal-title":"J. Diab."},{"issue":"2","key":"4070_CR41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00774-014-0581-y","volume":"33","author":"SK Hegazy","year":"2015","unstructured":"S.K. Hegazy, Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J. Bone Min. Metab. 33(2), 207\u2013212 (2015)","journal-title":"J. Bone Min. Metab."},{"issue":"8","key":"4070_CR42","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00198-017-4051-y","volume":"28","author":"S Dombrowski","year":"2017","unstructured":"S. Dombrowski, K. Kostev, L. Jacob, Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany\u2014A retrospective analysis of real-world data. Osteoporos. Int. 28(8), 2421\u20132428 (2017)","journal-title":"Osteoporos. Int."},{"issue":"1","key":"4070_CR43","doi-asserted-by":"crossref","first-page":"29104","DOI":"10.1038\/srep29104","volume":"6","author":"J Fu","year":"2016","unstructured":"J. Fu, J. Zhu, Y. Hao, C. Guo, Z. Zhou, Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci. Rep. 6(1), 29104 (2016)","journal-title":"Sci. Rep."},{"issue":"01","key":"4070_CR44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5414\/CP204266","volume":"61","author":"K Ohyama","year":"2023","unstructured":"K. Ohyama, T. Okamoto, Y. Hori, Inverse association between DPP-4 inhibitor use and fracture in older adults: a disproportionality analysis of the FAERS and JADER. Int J. Clin. Pharm. Ther. 61(01), 16\u201323 (2023)","journal-title":"Int J. Clin. Pharm. Ther."},{"issue":"20","key":"4070_CR45","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.3390\/jcm10204775","volume":"10","author":"D-H Lee","year":"2021","unstructured":"D.-H. Lee, K.Y. Kim, M.Y. Yoo, H. Moon, E.J. Ku, T.K. Oh et al. Effect of dipeptidyl peptidase-4 inhibitors on bone health in patients with type 2 diabetes mellitus. J. Clin. Med. 10(20), 4775 (2021)","journal-title":"J. Clin. Med."},{"issue":"7","key":"4070_CR46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/JCMA.0000000000000743","volume":"85","author":"C-H Chang","year":"2022","unstructured":"C.-H. Chang, C.H. Lu, C.-H. Chung, S.-C. Su, F.-C. Kuo, J.-S. Liu et al. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan. J. Chin. Med Assoc. 85(7), 747\u2013753 (2022)","journal-title":"J. Chin. Med Assoc."},{"issue":"1","key":"4070_CR47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00774-022-01372-0","volume":"41","author":"J Tamaki","year":"2023","unstructured":"J. Tamaki, S. Ogawa, K. Fujimori, S. Ishii, S. Nakatoh, N. Okimoto et al. Hip and vertebral fracture risk after initiating antidiabetic drugs in Japanese elderly: a nationwide study. J. Bone Min. Metab. 41(1), 29\u201340 (2023)","journal-title":"J. Bone Min. Metab."},{"issue":"6","key":"4070_CR48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s11914-020-00638-8","volume":"18","author":"Z Al-Mashhadi","year":"2020","unstructured":"Z. Al-Mashhadi, R. Viggers, R. Fuglsang-Nielsen, F. de Vries, J.P. van den Bergh, T. Harsl\u00f8f et al. Glucose-lowering drugs and fracture risk-a systematic review. Curr. Osteoporos. Rep. 18(6), 737\u2013758 (2020)","journal-title":"Curr. Osteoporos. Rep."},{"key":"4070_CR49","unstructured":"Latif W., Lambrinos K.J., Rodriguez R. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). StatPearls. (2024). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33567185"},{"issue":"S3","key":"4070_CR50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"MA Nauck","year":"2021","unstructured":"M.A. Nauck, D.R. Quast, J. Wefers, A.F.H. Pfeiffer, The evolving story of incretins (<scp>GIP<\/scp> and <scp>GLP<\/scp> \u20101) in metabolic and cardiovascular disease: a pathophysiological update. Diab. Obes. Metab. 23(S3), 5\u201329 (2021)","journal-title":"Diab. Obes. Metab."},{"issue":"S1","key":"4070_CR51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"M.A. Nauck, J.J. Meier, Incretin hormones: their role in health and disease. Diab. Obes. Metab. 20(S1), 5\u201321 (2018)","journal-title":"Diab. Obes. Metab."},{"key":"4070_CR52","doi-asserted-by":"crossref","unstructured":"Viggers R., Rasmussen N.H., Vestergaard P. Effects of incretin therapy on skeletal health in type 2 diabetes\u2014a systematic review. JBMR Plus. 7(11) (2023). https:\/\/asbmr.onlinelibrary.wiley.com\/doi\/10.1002\/jbm4.10817","DOI":"10.1002\/jbm4.10817"},{"issue":"4","key":"4070_CR53","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.stemcr.2016.02.002","volume":"6","author":"J Meng","year":"2016","unstructured":"J. Meng, X. Ma, N. Wang, M. Jia, L. Bi, Y. Wang et al. Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through \u03b2-catenin. Stem Cell Rep. 6(4), 579\u2013591 (2016)","journal-title":"Stem Cell Rep."},{"issue":"4","key":"4070_CR54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MED.0000000000000813","volume":"30","author":"J Starup-Linde","year":"2023","unstructured":"J. Starup-Linde, K. Hygum, B. Langdahl, Effect of incretins on skeletal health. Curr. Opin. Endocrinol. Diab. Obes. 30(4), 206\u2013212 (2023)","journal-title":"Curr. Opin. Endocrinol. Diab. Obes."},{"issue":"4","key":"4070_CR55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1753-0407.2010.00079.x","volume":"2","author":"Z Bloomgarden","year":"2010","unstructured":"Z. Bloomgarden, Liraglutide and calcitonin. J. Diabetes 2(4), 223\u2013224 (2010)","journal-title":"J. Diabetes"},{"issue":"2","key":"4070_CR56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"J. Bezin, A. Gouverneur, M. P\u00e9nichon, C. Mathieu, R. Garrel, D. Hillaire-Buys et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diab. Care 46(2), 384\u2013390 (2023)","journal-title":"Diab. Care"},{"issue":"2\u20133","key":"4070_CR57","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0014-5793(96)00895-2","volume":"393","author":"Y Lamari","year":"1996","unstructured":"Y. Lamari, C. Boissard, M.S. Moukhtar, A. Jullienne, G. Rosselin, J.-M. Garel, Expression of glucagon\u2010like peptide 1 receptor in a murine C cell line regulation of calcitonin gene by glucagon\u2010like peptide 1. FEBS Lett. 393(2\u20133), 248\u2013252 (1996)","journal-title":"FEBS Lett."},{"issue":"1","key":"4070_CR58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","volume":"97","author":"B Gier","year":"2012","unstructured":"B. Gier, P.C. Butler, C.K. Lai, D. Kirakossian, M.M. DeNicola, M.W. Yeh, Glucagon like peptide-1 receptor expression in the human thyroid gland. J. Clin. Endocrinol. Metab. 97(1), 121\u2013131 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4070_CR59","first-page":"1","volume":"2020","author":"J Xie","year":"2020","unstructured":"J. Xie, J. Guo, Z. Kanwal, M. Wu, X. Lv, N.A. Ibrahim et al. Calcitonin and bone physiology: in vitro, in vivo, and clinical investigations. Int. J. Endocrinol. 2020, 1\u201320 (2020)","journal-title":"Int. J. Endocrinol."},{"issue":"5","key":"4070_CR60","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2009.07.008","volume":"45","author":"DB Henriksen","year":"2009","unstructured":"D.B. Henriksen, P. Alexandersen, B. Hartmann, C.L. Adrian, I. Byrjalsen, H.G. Bone et al. Four-month treatment with GLP-2 significantly increases hip BMD. Bone 45(5), 833\u2013842 (2009)","journal-title":"Bone"},{"issue":"4","key":"4070_CR61","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","volume":"13","author":"MC Bunck","year":"2011","unstructured":"M.C. Bunck, B. Eliasson, A. Corn\u00e9r, R.J. Heine, R.M. Shaginian, M.-R. Taskinen et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diab. Obes. Metab. 13(4), 374\u2013377 (2011)","journal-title":"Diab. Obes. Metab."},{"key":"4070_CR62","doi-asserted-by":"crossref","unstructured":"Cai T., Li H., Jiang L., Wang H., Luo M., Su X., et al. Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study. Mohankumar S., editor. Biomed. Res. Int. 17, 1\u20138 (2021). https:\/\/www.hindawi.com\/journals\/bmri\/2021\/3361309\/","DOI":"10.1155\/2021\/3361309"},{"issue":"1","key":"4070_CR63","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/21551197.2018.1564721","volume":"38","author":"BC Jiang","year":"2019","unstructured":"B.C. Jiang, D.T. Villareal, Weight loss-induced reduction of bone mineral density in older adults with obesity. J. Nutr. Gerontol. Geriatr. 38(1), 100\u2013114 (2019)","journal-title":"J. Nutr. Gerontol. Geriatr."},{"key":"4070_CR64","doi-asserted-by":"crossref","first-page":"115197","DOI":"10.1016\/j.bone.2019.115197","volume":"132","author":"K Hygum","year":"2020","unstructured":"K. Hygum, T. Harsl\u00f8f, N.R. J\u00f8rgensen, J. Rungby, S.B. Pedersen, B.L. Langdahl, Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone 132, 115197 (2020)","journal-title":"Bone"},{"issue":"6","key":"4070_CR65","doi-asserted-by":"crossref","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","volume":"7","author":"SBK Jensen","year":"2024","unstructured":"S.B.K. Jensen, V. S\u00f8rensen, R.M. Sandsdal, E.W. Lehmann, J.R. Lundgren, C.R. Juhl et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Netw. Open 7(6), e2416775 (2024)","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"4070_CR66","doi-asserted-by":"crossref","first-page":"108529","DOI":"10.1016\/j.jdiacomp.2023.108529","volume":"37","author":"D Patoulias","year":"2023","unstructured":"D. Patoulias, D.S. Popovic, A.P. Stoian, A. Janez, A. Sahebkar, M. Rizzo, Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: a systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials. J. Diab. Complic. 37(8), 108529 (2023)","journal-title":"J. Diab. Complic."},{"key":"4070_CR67","doi-asserted-by":"crossref","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","volume":"72","author":"MS Hansen","year":"2024","unstructured":"M.S. Hansen, E.M. W\u00f6lfel, S. Jeromdesella, J.-J.K. M\u00f8ller, C. Ejersted, N.R. J\u00f8rgensen et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. eClinicalMedicine 72, 102624 (2024)","journal-title":"eClinicalMedicine"},{"issue":"1","key":"4070_CR68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-014-0361-4","volume":"48","author":"B Su","year":"2015","unstructured":"B. Su, H. Sheng, M. Zhang, L. Bu, P. Yang, L. Li et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists\u2019 treatment: a meta-analysis of randomized controlled trials. Endocrine 48(1), 107\u2013115 (2015)","journal-title":"Endocrine"},{"issue":"3","key":"4070_CR69","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1753-0407.12102","volume":"6","author":"G Mabilleau","year":"2014","unstructured":"G. Mabilleau, A. Mieczkowska, D. Chappard, Use of glucagon\u2010like peptide\u20101 receptor agonists and bone fractures: A meta\u2010analysis of randomized clinical trials. J. Diabetes 6(3), 260\u2013266 (2014)","journal-title":"J. Diabetes"},{"issue":"12","key":"4070_CR70","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s00198-018-4649-8","volume":"29","author":"YS Zhang","year":"2018","unstructured":"Y.S. Zhang, W.Y. Weng, B.C. Xie, Y. Meng, Y.H. Hao, Y.M. Liang et al. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos. Int. 29(12), 2639\u20132644 (2018)","journal-title":"Osteoporos. Int."},{"key":"4070_CR71","doi-asserted-by":"crossref","unstructured":"Al-Mashhadi Z.K., Viggers R., Fuglsang-Nielsen R., Vestergaard P., Gregersen S., Starup-Linde J. The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: a Danish nationwide cohort study. Front. Endocrinol. 13 (2022). https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.882998\/full","DOI":"10.3389\/fendo.2022.882998"},{"issue":"39","key":"4070_CR72","doi-asserted-by":"crossref","first-page":"e35394","DOI":"10.1097\/MD.0000000000035394","volume":"102","author":"OZ Akyay","year":"2023","unstructured":"O.Z. Akyay, Z. Canturk, A. Selek, B. Cetinarslan, \u0130. Tarkun, Y. Cakmak et al. The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus. Medicine 102(39), e35394 (2023)","journal-title":"Medicine"},{"issue":"4","key":"4070_CR73","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MNH.0000000000000505","volume":"28","author":"JSJ Vinke","year":"2019","unstructured":"J.S.J. Vinke, H.J.L. Heerspink, M.H. de Borst, Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus. Curr. Opin. Nephrol. Hypertens. 28(4), 321\u2013327 (2019)","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"2","key":"4070_CR74","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"D.K. McGuire, W.J. Shih, F. Cosentino, B. Charbonnel, D.Z.I. Cherney, S. Dagogo-Jack et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. JAMA Cardiol. 6(2), 148 (2021)","journal-title":"JAMA Cardiol."},{"issue":"8","key":"4070_CR75","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/03007995.2016.1174841","volume":"32","author":"M Alba","year":"2016","unstructured":"M. Alba, J. Xie, A. Fung, M. Desai, The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr. Med. Res. Opin. 32(8), 1375\u20131385 (2016)","journal-title":"Curr. Med. Res. Opin."},{"key":"4070_CR76","doi-asserted-by":"crossref","unstructured":"Blau J.E., Bauman V., Conway E.M., Piaggi P., Walter M.F., Wright E.C., et al. Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight. 3(8) (2018). https:\/\/insight.jci.org\/articles\/view\/99123","DOI":"10.1172\/jci.insight.99123"},{"issue":"1","key":"4070_CR77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","volume":"5","author":"R Santer","year":"2010","unstructured":"R. Santer, J. Calado, Familial renal glucosuria and SGLT2. Clin. J. Am. Soc. Nephrol. 5(1), 133\u2013141 (2010)","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"7","key":"4070_CR78","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.3390\/ijms24076278","volume":"24","author":"K Unno","year":"2023","unstructured":"K. Unno, K. Taguchi, Y. Takagi, T. Hase, S. Meguro, Y. Nakamura, Mouse models with SGLT2 mutations: toward understanding the role of SGLT2 beyond glucose reabsorption. Int J. Mol. Sci. 24(7), 6278 (2023)","journal-title":"Int J. Mol. Sci."},{"key":"4070_CR79","doi-asserted-by":"crossref","first-page":"115254","DOI":"10.1016\/j.bone.2020.115254","volume":"133","author":"KM Thrailkill","year":"2020","unstructured":"K.M. Thrailkill, R.C. Bunn, S. Uppuganti, P. Ray, K. Garrett, I. Popescu et al. Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone. Bone 133, 115254 (2020)","journal-title":"Bone"},{"issue":"1","key":"4070_CR80","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"J.P. Bilezikian, N.B. Watts, K. Usiskin, D. Polidori, A. Fung, D. Sullivan et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J. Clin. Endocrinol. Metab. 101(1), 44\u201351 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"4070_CR81","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","volume":"14","author":"\u00d6 Ljunggren","year":"2012","unstructured":"\u00d6. Ljunggren, J. Bolinder, L. Johansson, J. Wilding, A.M. Langkilde, C.D. Sj\u00f6str\u00f6m et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diab. Obes. Metab. 14(11), 990\u2013999 (2012)","journal-title":"Diab. Obes. Metab."},{"key":"4070_CR82","doi-asserted-by":"crossref","unstructured":"Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(21), 2097\u20132099 (2017). http:\/\/www.nejm.org\/doi\/10.1056\/NEJMc1712572","DOI":"10.1056\/NEJMc1712572"},{"issue":"1","key":"4070_CR83","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"N.B. Watts, J.P. Bilezikian, K. Usiskin, R. Edwards, M. Desai, G. Law et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 101(1), 157\u2013166 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4070_CR84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/M18-0567","volume":"170","author":"M Fralick","year":"2019","unstructured":"M. Fralick, S.C. Kim, S. Schneeweiss, D. Kim, D.A. Redelmeier, E. Patorno, Fracture risk after initiation of use of canagliflozin. Ann. Intern. Med. 170(3), 155 (2019)","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"4070_CR85","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"D.E. Kohan, P. Fioretto, W. Tang, J.F. List, Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85(4), 962\u2013971 (2014)","journal-title":"Kidney Int."},{"issue":"5","key":"4070_CR86","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.diabet.2019.01.010","volume":"45","author":"L Cheng","year":"2019","unstructured":"L. Cheng, Y.-Y. Li, W. Hu, F. Bai, H.-R. Hao, W.-N. Yu et al. Risk of bone fracture associated with sodium\u2013glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diab. Metab. 45(5), 436\u2013445 (2019)","journal-title":"Diab. Metab."},{"key":"4070_CR87","doi-asserted-by":"crossref","unstructured":"Al-Mashhadi Z.K., Viggers R., Starup-Linde J., Vestergaard P., Gregersen S. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: a nationwide cohort study. Front. Endocrinol. 13 (2022). https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.861422\/full","DOI":"10.3389\/fendo.2022.861422"},{"issue":"9","key":"4070_CR88","doi-asserted-by":"crossref","first-page":"e2335797","DOI":"10.1001\/jamanetworkopen.2023.35797","volume":"6","author":"HY Ko","year":"2023","unstructured":"H.Y. Ko, S. Bea, H.E. Jeong, S. Park, Y.M. Cho, S.H. Kong et al. Sodium-glucose cotransporter 2 inhibitors vs incretin-based drugs and risk of fractures for type 2 diabetes. JAMA Netw. Open 6(9), e2335797 (2023)","journal-title":"JAMA Netw. Open"},{"key":"4070_CR89","doi-asserted-by":"crossref","unstructured":"Patorno E., Najafzadeh M., Pawar A., Franklin J.M., D\u00e9ruaz\u2010Luyet A., Brodovicz K.G., et al. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinol. Diabetes Metab. 3(1). (2020). https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.103","DOI":"10.1002\/edm2.103"},{"issue":"10","key":"4070_CR90","doi-asserted-by":"crossref","first-page":"e2130762","DOI":"10.1001\/jamanetworkopen.2021.30762","volume":"4","author":"M Zhuo","year":"2021","unstructured":"M. Zhuo, C.E. Hawley, J.M. Paik, L.G. Bessette, D.J. Wexler, D.H. Kim et al. Association of sodium-glucose cotransporter\u20132 inhibitors with fracture risk in older adults with type 2 diabetes. JAMA Netw. Open 4(10), e2130762 (2021)","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"4070_CR91","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","volume":"183","author":"E D\u2019Andrea","year":"2023","unstructured":"E. D\u2019Andrea, D.J. Wexler, S.C. Kim, J.M. Paik, E. Alt, E. Patorno, Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA 1c levels. JAMA Intern. Med. 183(3), 242 (2023)","journal-title":"JAMA Intern. Med."},{"issue":"12","key":"4070_CR92","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00198-023-06908-2","volume":"34","author":"X Wang","year":"2023","unstructured":"X. Wang, F. Zhang, Y. Zhang, J. Zhang, Y. Sheng, W. Wang et al. Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporos. Int. 34(12), 2013\u20132025 (2023)","journal-title":"Osteoporos. Int."},{"key":"4070_CR93","doi-asserted-by":"crossref","unstructured":"Chai S., Liu F., Yang Z., Yu S., Liu Z., Yang Q., et al. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks. Front. Pharmacol. 13 (2022). https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.825417\/full","DOI":"10.3389\/fphar.2022.825417"},{"issue":"12","key":"4070_CR94","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.3390\/ijms22126403","volume":"22","author":"MS Rahman","year":"2021","unstructured":"M.S. Rahman, K.S. Hossain, S. Das, S. Kundu, E.O. Adegoke, M.A. Rahman et al. Role of insulin in health and disease: an update. Int. J. Mol. Sci. 22(12), 6403 (2021)","journal-title":"Int. J. Mol. Sci."},{"key":"4070_CR95","doi-asserted-by":"crossref","unstructured":"Ducy P. Bone regulation of insulin secretion and glucose homeostasis. Endocrinology 161(10) (2020). https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqaa149\/5895464","DOI":"10.1210\/endocr\/bqaa149"},{"issue":"7","key":"4070_CR96","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1172\/JCI9017","volume":"105","author":"N Ogata","year":"2000","unstructured":"N. Ogata, D. Chikazu, N. Kubota, Y. Terauchi, K. Tobe, Y. Azuma et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J. Clin. Investig. 105(7), 935\u2013943 (2000)","journal-title":"J. Clin. Investig."},{"issue":"5","key":"4070_CR97","first-page":"E735","volume":"289","author":"KM Thrailkill","year":"2005","unstructured":"K.M. Thrailkill, C.K. Lumpkin, R.C. Bunn, S.F. Kemp, J.L. Fowlkes, Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am. J. Physiol. Metab. 289(5), E735\u2013E745 (2005)","journal-title":"Am. J. Physiol. Metab."},{"issue":"10","key":"4070_CR98","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2337\/dc15-0783","volume":"38","author":"DR Weber","year":"2015","unstructured":"D.R. Weber, K. Haynes, M.B. Leonard, S.M. Willi, M.R. Denburg, Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using the health improvement network (THIN). Diab. Care 38(10), 1913\u20131920 (2015)","journal-title":"Diab. Care"},{"issue":"3","key":"4070_CR99","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cen.13761","volume":"89","author":"EP Thong","year":"2018","unstructured":"E.P. Thong, M. Herath, D.R. Weber, S. Ranasinha, P.R. Ebeling, F. Milat et al. Fracture risk in young and middle\u2010aged adults with type 1 diabetes mellitus: A systematic review and meta\u2010analysis. Clin. Endocrinol. 89(3), 314\u2013323 (2018)","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"4070_CR100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s001980070114","volume":"11","author":"MM Campos Pastor","year":"2000","unstructured":"M.M. Campos Pastor, P.J. L\u00f3pez-Ibarra, F. Escobar-Jim\u00e9nez, M.D. Serrano Pardo, A. Garc\u00eda-Cervig\u00f3n, Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos. Int. 11(5), 455\u2013459 (2000)","journal-title":"Osteoporos. Int."},{"issue":"10","key":"4070_CR101","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2337\/diacare.25.10.1749","volume":"25","author":"AV Schwartz","year":"2002","unstructured":"A.V. Schwartz, T.A. Hillier, D.E. Sellmeyer, H.E. Resnick, E. Gregg, K.E. Ensrud et al. Older women with diabetes have a higher risk of falls. Diab. Care 25(10), 1749\u20131754 (2002)","journal-title":"Diab. Care"},{"issue":"7","key":"4070_CR102","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2337\/diacare.24.7.1192","volume":"24","author":"KK Nicodemus","year":"2001","unstructured":"K.K. Nicodemus, A.R. Folsom, Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diab. Care 24(7), 1192\u20131197 (2001)","journal-title":"Diab. Care"},{"issue":"10","key":"4070_CR103","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00125-014-3289-6","volume":"57","author":"N Napoli","year":"2014","unstructured":"N. Napoli, E.S. Strotmeyer, K.E. Ensrud, D.E. Sellmeyer, D.C. Bauer, A.R. Hoffman et al. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 57(10), 2057\u20132065 (2014)","journal-title":"Diabetologia"},{"issue":"2","key":"4070_CR104","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1210\/er.2012-1042","volume":"36","author":"MP Gilbert","year":"2015","unstructured":"M.P. Gilbert, R.E. Pratley, The impact of diabetes and diabetes medications on bone health. Endocr. Rev. 36(2), 194\u2013213 (2015)","journal-title":"Endocr. Rev."},{"issue":"6","key":"4070_CR105","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00774-012-0374-0","volume":"30","author":"C Wang","year":"2012","unstructured":"C. Wang, H. Li, S.-G. Chen, J.-W. He, C.-J. Sheng, X.-Y. Cheng et al. The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice. J. Bone Min. Metab. 30(6), 630\u2013637 (2012)","journal-title":"J. Bone Min. Metab."},{"issue":"11","key":"4070_CR106","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1463-1326.2011.01461.x","volume":"13","author":"JLC Borges","year":"2011","unstructured":"J.L.C. Borges, J.P. Bilezikian, A.R. Jones-Leone, A.P. Acusta, P.D. Ambery, A.J. Nino et al. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone\/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-na\u00efve type 2 d. Diab. Obes. Metab. 13(11), 1036\u20131046 (2011)","journal-title":"Diab. Obes. Metab."},{"issue":"18","key":"4070_CR107","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.12998\/wjcc.v8.i18.4010","volume":"8","author":"L-X Wang","year":"2020","unstructured":"L.-X. Wang, G.-Y. Wang, N. Su, J. Ma, Y.-K. Li, Effects of different doses of metformin on bone mineral density and bone metabolism in elderly male patients with type 2 diabetes mellitus. World J. Clin. Cases 8(18), 4010\u20134016 (2020)","journal-title":"World J. Clin. Cases"},{"issue":"2","key":"4070_CR108","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1210\/en.2006-1121","volume":"148","author":"B Lecka-Czernik","year":"2007","unstructured":"B. Lecka-Czernik, C. Ackert-Bicknell, M.L. Adamo, V. Marmolejos, G.A. Churchill, K.R. Shockley et al. Activation of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148(2), 903\u2013911 (2007)","journal-title":"Endocrinology"},{"issue":"1","key":"4070_CR109","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/en.2003-0746","volume":"145","author":"SO Rzonca","year":"2004","unstructured":"S.O. Rzonca, L.J. Suva, D. Gaddy, D.C. Montague, B. Lecka-Czernik, Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145(1), 401\u2013406 (2004)","journal-title":"Endocrinology"},{"issue":"1","key":"4070_CR110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1677\/joe.1.05723","volume":"183","author":"MA Soroc\u00e9anu","year":"2004","unstructured":"M.A. Soroc\u00e9anu, D. Miao, X.-Y. Bai, H. Su, D. Goltzman, A.C. Karaplis, Rosiglitazone impacts negatively on bone by promoting osteoblast\/osteocyte apoptosis. J. Endocrinol. 183(1), 203\u2013216 (2004)","journal-title":"J. Endocrinol."},{"issue":"3","key":"4070_CR111","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.metabol.2009.08.003","volume":"59","author":"P Ma","year":"2010","unstructured":"P. Ma, B. Gu, J. Ma, E L, X. Wu, J. Cao et al. Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase\/Akt pathway. Metabolism 59(3), 359\u2013366 (2010)","journal-title":"Metabolism"},{"issue":"1","key":"4070_CR112","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12777","volume":"81","author":"G Luo","year":"2016","unstructured":"G. Luo, H. Liu, H. Lu, Glucagon\u2010like peptide\u20101(GLP\u20101) receptor agonists: potential to reduce fracture risk in diabetic patients? Br. J. Clin. Pharm. 81(1), 78\u201388 (2016)","journal-title":"Br. J. Clin. Pharm."},{"issue":"10","key":"4070_CR113","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.lfs.2013.01.001","volume":"92","author":"J-Y Kim","year":"2013","unstructured":"J.-Y. Kim, S.-K. Lee, K.-J. Jo, D.-Y. Song, D.-M. Lim, K.-Y. Park et al. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST\/sclerostin in osteocytes. Life Sci. 92(10), 533\u2013540 (2013)","journal-title":"Life Sci."},{"key":"4070_CR114","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.01.028","volume":"727","author":"ML Sbaraglini","year":"2014","unstructured":"M.L. Sbaraglini, M.S. Molinuevo, C. Sedlinsky, L. Schurman, A.D. McCarthy, Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells. Eur. J. Pharm. 727, 8\u201314 (2014)","journal-title":"Eur. J. Pharm."},{"issue":"3","key":"4070_CR115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/dmrr.2466","volume":"30","author":"EJ Gallagher","year":"2014","unstructured":"E.J. Gallagher, H. Sun, C. Kornhauser, A. Tobin\u2010Hess, S. Epstein, S. Yakar, et al., The effect of dipeptidyl peptidase\u2010IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab. Res. Rev. 30(3), 191\u2013200 (2014)","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"1","key":"4070_CR116","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"A.J. Scheen, Pharmacodynamics, efficacy and safety of sodium\u2013glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75(1), 33\u201359 (2015)","journal-title":"Drugs"},{"key":"4070_CR117","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","volume":"727","author":"M Yokono","year":"2014","unstructured":"M. Yokono, T. Takasu, Y. Hayashizaki, K. Mitsuoka, R. Kihara, Y. Muramatsu et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur. J. Pharm. 727, 66\u201374 (2014)","journal-title":"Eur. J. Pharm."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04070-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04070-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04070-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:20:48Z","timestamp":1740147648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04070-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":117,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["4070"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04070-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}